NEW YORK (TheStreet) -- RATINGS CHANGES
Aquinox Pharmaceuticals (AQXP) was downgraded to hold from buy by Jefferies, which set a $2 price target, saying the company reported PII proof-of-concept FLAGSHIP trial data and suggested that AQX-1125 failed to observe any difference in the exacerbation rate in COPD patients vs. placebo.
Cameron (CAM) was upgraded to outperform by RBC Capital, which set a $65 price target, saying that Cameron's surface and subsea businesses should drive growth over the next several quarters.
Costco(COST) - Get Report was upgraded to outperform by Oppenheimer, which set a $160 price target, saying the stock has lagged, but the company may raise membership fees and will likely cut back on technology spending.
Foru Energy Technologies(FET) - Get Report was upgraded to hold from underperform by Jefferies, which set a $19 price target, saying the company has notable free-cash-flow generation potential as the industry "settles into the bottom" and merger-and-acquisition potential ratchets up (and/or share buyback potential).
IntercontinentalExchange(ICE) - Get Report was upgraded to buy from hold by Deutsche Bank, which set a $252 price target. Deutsche Bank cited valuation, as the stock has underperformed over the past eight months.
Quintles (Q) was upgraded to overweight by Keybanc, which set an $84 price target, saying that higher clinical trial activity should boost profit growth.
Superior Energy Services (SPN) was upgraded to buy from hold by Jefferies, which set a $25 price target, saying that the company can fully participate in the expected recovery of activity globally and it has earnings power in excess of $2/share.
Weatherford International(WFT) - Get Report was upgraded to buy from hold by Jefferies, which set a $14 price target, saying it acknowledge the changes in the organization and models free cash flow beginning in 2016 and exceeding $1 billion per year on a normalized basis.